Workflow
Ocular Therapeutix(OCUL)
icon
Search documents
Ocular Therapeutix(OCUL) - 2022 Q2 - Quarterly Report
2022-08-08 20:14
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdic ...
Ocular Therapeutix(OCUL) - 2022 Q1 - Earnings Call Transcript
2022-05-10 03:30
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Donald Notman – Chief Financial Officer Antony Mattessich – President & Chief Executive Officer Michael Goldstein – Chief Medical Officer Conference Call Participants Joe Catanzaro – Piper Sandler Dane Leone – Raymond James Jon Wollenben – JMP Securities Yi Chen – H.C. Wainwright Anita Dushyanth – Berenberg Capital Operator Good afternoon, ladies and gentlemen, thank you for standing by. And w ...
Ocular Therapeutix(OCUL) - 2022 Q1 - Quarterly Report
2022-05-09 20:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdi ...
Ocular Therapeutix(OCUL) - 2021 Q4 - Earnings Call Transcript
2022-03-01 03:56
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Executive Officer Michael Goldstein - Chief Medical Officer Conference Call Participants Joe Catanzaro - Piper Sandler Jon Wolleben - JMP Securities Dane Leone - Raymond James Yi Chen - H.C. Wainwright Anita Dushyanth - Berenberg Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by a ...
Ocular Therapeutix(OCUL) - 2021 Q4 - Annual Report
2022-02-28 21:28
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (State or ...
Ocular Therapeutix(OCUL) - 2021 Q3 - Earnings Call Transcript
2021-11-09 02:58
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants Antony Mattessich – CEO Donald Notman – CFO Dr. Michael Goldstein – Chief Medical Officer Scott Corning – Senior Vice President Commercial Chris White – Chief Business Officer Conference Call Participants Jon Wolleben – Participants Dane Leone – Raymond James Joe Catanzaro – Piper Sandler David Steinberg – Jefferies Anita Dushyanth – Berenberg Capital Georgi Yordanov – Cowen and Company Y ...
Ocular Therapeutix(OCUL) - 2021 Q3 - Quarterly Report
2021-11-08 21:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) Delaware 20-5560161 24 Crosby Drive Bedford, MA 01730 (Address of principal executive offices) (Zip ...
Ocular Therapeutix(OCUL) - 2021 Q2 - Earnings Call Transcript
2021-08-10 01:22
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2021 Results Conference Call August 9, 2021 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President and Chief Executive Officer Dr. Michael Goldstein - President-Ophthalmology and Chief Medical Officer Scott Corning - Senior Vice President, Commercial Chris White - Senior Vice President, Business and Corporate Development Conference Call Participants Jon Wolleben - JMP Securities Joe Catanzaro - Piper Sandler Georgi Yord ...
Ocular Therapeutix(OCUL) - 2021 Q2 - Quarterly Report
2021-08-09 20:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 (Address of principal executive offices) (Zip Code) (781) 357-4000 (Registrant's telephone number, inclu ...
Ocular Therapeutix(OCUL) - 2021 Q1 - Earnings Call Transcript
2021-05-06 01:45
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Donald Notman – Chief Financial Officer Antony Mattessich – President and Chief Executive Officer Michael Goldstein – President-Ophthalmology and Chief Medical Officer Conference Call Participants Joe Catanzaro – Piper Sandler Jonathan Wollenben – JMP Securities Georgi Yordanov – Cowen and Company Ed Chung – Jefferies Anita Dushyanth – Berenberg Boobalan Pachaiyappan – H.C. Wainwright Operator ...